C. Braudeau, A. Néel, K. Amouriaux, J. C. Martin, M. Rimbert et al., Dysregulated responsiveness of circulating dendritic cells to Toll-like receptors in ANCA-associated vasculitis, Front Immunol, vol.8, p.102, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02156159

C. Braudeau, K. Amouriaux, A. Néel, G. Herbreteau, N. Salabert et al., Persistent deficiency of circulating mucosalassociated invariant T (MAIT) cells in ANCA-associated vasculitis, J Autoimmun, vol.70, pp.73-82, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02150784

C. G. Kallenberg, C. A. Stegeman, W. H. Abdulahad, and P. Heeringa, Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention, Am J Kidney Dis, vol.62, pp.1176-87, 2013.

M. Rimbert, M. Hamidou, C. Braudeau, X. Puéchal, L. Teixeira et al., Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibodyassociated vasculitis, PLoS One, vol.6, p.18734, 2011.

E. F. Mckinney, P. A. Lyons, E. J. Carr, J. L. Hollis, D. R. Jayne et al., A CD8+ T cell transcription signature predicts prognosis in autoimmune disease, Nat Med, vol.16, pp.586-91, 2010.

J. Chang, P. Eggenhuizen, K. M. O'sullivan, M. A. Alikhan, S. R. Holdsworth et al., CD8+ T cells effect glomerular injury in experimental anti-myeloperoxidase GN, J Am Soc Nephrol, vol.28, pp.47-55, 2017.

L. Guillevin, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaître et al., for the French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis, N Engl J Med, vol.371, pp.1771-80, 2014.

J. H. Stone, P. A. Merkel, R. Spiera, P. Seo, C. A. Langford et al., Rituximab versus cyclophosphamide for ANCA-associated vasculitis, N Engl J Med, vol.363, pp.221-253, 2010.

O. T. Chan, L. G. Hannum, A. M. Haberman, Z. Liu, M. Zhao et al., A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus, J Exp Med, vol.189, pp.1639-1687, 1999.

T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch et al., B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells, J Exp Med, vol.209, pp.1001-1011, 2012.

F. E. Lund and T. D. Randall, Effector and regulatory B cells: modulators of CD4+ T cell immunity, Nat Rev Immunol, vol.10, pp.236-283, 2010.

Y. Zhao, P. M. Lutalo, J. E. Thomas, S. Sangle, L. M. Choong et al., Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis, Rheumatology (Oxford), vol.53, pp.621-651, 2014.

B. Afzali, P. J. Mitchell, F. C. Edozie, G. A. Povoleri, S. E. Dowson et al., CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner, Eur J Immunol, vol.43, pp.2043-54, 2013.

A. M. Pesenacker, D. Bending, S. Ursu, Q. Wu, K. Nistala et al., CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines, Blood, vol.121, pp.2647-58, 2013.

J. Verhagen and D. C. Wraith, Expression of Helios, an Ikaros transcription factor family member, differentiates thymicderived from peripherally induced Foxp3+ T regulatory cells, J Immunol, vol.185, p.7129, 2010.

H. Takatori, H. Kawashima, A. Matsuki, K. Meguro, S. Tanaka et al., Helios enhances Treg cell function in cooperation with FoxP3, Arthritis Rheumatol, vol.67, pp.1491-502, 2015.

A. M. Thornton, P. E. Korty, D. Q. Tran, E. A. Wohlfert, P. E. Murray et al., Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells, J Immunol, vol.184, pp.3433-3474, 2010.

M. D. Morgan, A. Pachnio, J. Begum, D. Roberts, N. Rasmussen et al., CD4+CD28? T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality, Arthritis Rheum, vol.63, pp.2127-2164, 2011.

P. Eriksson, C. Sandell, K. Backteman, and J. Ernerudh, Expansions of CD4+CD28? and CD8+CD28? T cells in granulomatosis with polyangiitis and microscopic polyangiitis are associated with cytomegalovirus infection but not with disease activity, J Rheumatol, vol.39, pp.1840-1843, 2012.

R. Stasi, N. Cooper, D. Poeta, G. Stipa, E. Evangelista et al., Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab, Blood, vol.112, pp.1147-50, 2008.

F. L. Van-de-veerdonk, B. Lauwerys, R. J. Marijnissen, K. Timmermans, D. Padova et al., The anti-CD20 antibody rituximab reduces the Th17 cell response, Arthritis Rheum, vol.63, pp.1507-1523, 2011.

G. M. Verstappen, F. G. Kroese, P. M. Meiners, O. B. Corneth, M. G. Huitema et al., B cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome, J Rheumatol, vol.44, pp.49-58, 2017.

W. H. Abdulahad, C. A. Stegeman, Y. M. Van-der-geld, B. Doornbos-van-der-meer, P. C. Limburg et al., Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission, Arthritis Rheum, vol.56, pp.2080-91, 2007.

M. D. Morgan, C. J. Day, K. P. Piper, N. Khan, L. Harper et al., Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells, Immunology, vol.130, pp.64-73, 2010.

M. E. Free, D. O. Bunch, J. A. Mcgregor, B. E. Jones, E. A. Berg et al., Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population, Arthritis Rheum, vol.65, pp.1922-1955, 2013.

D. Saadoun, M. Rosenzwajg, D. Landau, J. C. Piette, D. Klatzmann et al., Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis, Blood, vol.111, pp.5334-5375, 2008.

M. Feuchtenberger, S. Müller, P. Roll, A. Waschbisch, A. Schäfer et al., Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis, Open Rheumatol J, vol.2, pp.81-89, 2008.

C. Díaz-torné, O. De-juana, M. A. Geli, C. Cantó, E. Laiz et al., Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis, Immunology, vol.142, pp.354-62, 2014.

M. Vigna-perez, B. Hernández-castro, O. Paredes-saharopulos, D. Portales-pérez, L. Baranda et al., Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study, Arthritis Res Ther, vol.8, p.83, 2006.

T. Vallerskog, I. Gunnarsson, M. Widhe, A. Risselada, L. Klareskog et al., Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE, Clin Immunol, vol.122, pp.62-74, 2007.

M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing et al., Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor, Immunity, vol.30, pp.899-911, 2009.

C. Deligne, A. Metidji, W. H. Fridman, and J. L. Teillaud, Anti-CD20 therapy induces a memory Th1 response through the IFN-?/IL-12 axis and prevents protumor regulatory T-cell expansion in mice, Leukemia, vol.29, pp.947-57, 2015.

H. Fujinaka, T. Yamamoto, L. Feng, M. Nameta, G. Garcia et al., Anti-perforin antibody treatment ameliorates experimental crescentic glomerulonephritis in WKY rats, Kidney Int, vol.72, pp.823-853, 2007.

J. Reynolds, V. A. Norgan, U. Bhambra, J. Smith, H. T. Cook et al., Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis, J Am Soc Nephrol, vol.13, pp.359-69, 2002.

R. Eming, A. Nagel, S. Wolff-franke, E. Podstawa, D. Debus et al., Rituximab exerts a dual effect in pemphigus vulgaris, J Invest Dermatol, vol.128, pp.2850-2858, 2008.

E. M. Vital, S. Dass, M. H. Buch, K. Henshaw, C. T. Pease et al., B cell biomarkers of rituximab responses in systemic lupus erythematosus, Arthritis Rheum, vol.63, pp.3038-3085, 2011.

S. Dass, A. C. Rawstron, E. M. Vital, K. Henshaw, D. Mcgonagle et al., Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis, Arthritis Rheum, vol.58, pp.2993-3002, 2008.

M. Yusof, M. Y. Vital, E. M. Das, S. Dass, S. Arumugakani et al., Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions, Ann Rheum Dis, vol.74, pp.1734-1742, 2015.

D. O. Bunch, J. G. Mcgregor, N. B. Khandoobhai, L. T. Aybar, M. E. Burkart et al., , p.5

, + B cells in active ANCA vasculitis and relapse after rituximab, Clin J Am Soc Nephrol, vol.8, pp.382-91, 2013.

D. O. Bunch, C. E. Mendoza, L. T. Aybar, E. S. Kotzen, K. R. Colby et al., Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis, Ann Rheum Dis, vol.74, pp.1784-1790, 2015.

, Applications Invited for Arthritis & Rheumatology Editor-in-Chief, 2020.

, ACR members who are considering applying should submit a nonbinding letter of intent by May 1, 2019 to the Managing Editor, Jane Diamond, at jdiamond@rheumatology.org, and are also encouraged to contact the current Editor-in-Chief, Dr. Richard Bucala, to discuss details; initial contact should be made via e-mail to richard, The American College of Rheumatology Committee on Journal Publications announces the search for the position of Editor, Arthritis & Rheumatology. The official term of the next Arthritis & Rheumatology editorship is, 2019.

,